Wilmington Savings Fund Society FSB Acquires 552 Shares of IQVIA Holdings Inc. $IQV

Wilmington Savings Fund Society FSB grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 6.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,753 shares of the medical research company’s stock after acquiring an additional 552 shares during the period. Wilmington Savings Fund Society FSB’s holdings in IQVIA were worth $1,379,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd raised its position in IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC increased its holdings in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA in the 1st quarter valued at $33,000. Trust Co. of Toledo NA OH bought a new stake in shares of IQVIA in the 2nd quarter worth about $39,000. Finally, Larson Financial Group LLC increased its holdings in shares of IQVIA by 109.9% in the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock worth $48,000 after buying an additional 144 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 0.7%

NYSE:IQV opened at $203.38 on Thursday. The firm has a market capitalization of $34.58 billion, a P/E ratio of 29.43, a PEG ratio of 2.25 and a beta of 1.32. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $237.21. The company’s fifty day moving average price is $190.38 and its 200-day moving average price is $168.79. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on IQV shares. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, July 23rd. Jefferies Financial Group raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Mizuho boosted their price target on shares of IQVIA from $190.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, July 25th. UBS Group boosted their price target on shares of IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. Finally, Evercore ISI boosted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $234.57.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.